Open access
Open access
Powered by Google Translator Translator

Differences in susceptibility of circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 to neutralization by convalescent plasma or vaccinee (Sinopharm or Sinovac) serum

7 Apr, 2021 | 01:57h | UTC

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization – New England Journal of Medicine

Related studies: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination – Nature Medicine AND Pfizer coronavirus vaccine found to be moderately less effective against B.1.351 variant AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well. AND RCT: Oxford/AstraZeneca vaccine does not protect against mild-to-moderate Covid-19 due to the B.1.351 variant AND New study of Coronavirus variants predicts virus evolving to escape current vaccines, treatments AND Moderna COVID-19 vaccine may be less effective against variant found in South Africa


Commentary on Twitter


Stay Updated in Your Specialty

No spam, just news.